Amedisys (AMED)
(Delayed Data from NSDQ)
$97.19 USD
+0.18 (0.19%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $97.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Income Statements
Fiscal Year end for Amedisys, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,236 | 2,223 | 2,227 | 2,106 | 1,956 |
Cost Of Goods | 1,246 | 1,260 | 1,233 | 1,185 | 1,150 |
Gross Profit | 991 | 963 | 994 | 921 | 805 |
Selling & Adminstrative & Depr. & Amort Expenses | 834 | 782 | 742 | 701 | 628 |
Income After Depreciation & Amortization | 156 | 181 | 252 | 219 | 177 |
Non-Operating Income | -86 | 2 | 38 | 3 | 7 |
Interest Expense | 31 | 22 | 10 | 11 | 15 |
Pretax Income | 40 | 160 | 280 | 211 | 170 |
Income Taxes | 51 | 43 | 70 | 26 | 43 |
Minority Interest | -1 | -1 | 1 | 2 | 1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -11 | 118 | 210 | 185 | 128 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | 119 | 209 | 184 | 127 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 215 | 253 | 324 | 288 | 233 |
Depreciation & Amortization (Cash Flow) | 59 | 72 | 72 | 69 | 55 |
Income After Depreciation & Amortization | 156 | 181 | 252 | 219 | 177 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 32.60 | 32.65 | 32.97 | 33.27 | 32.99 |
Diluted EPS Before Non-Recurring Items | 4.30 | 5.01 | 5.95 | 6.11 | 4.40 |
Diluted Net EPS (GAAP) | -0.30 | 3.63 | 6.34 | 5.52 | 3.84 |
Fiscal Year end for Amedisys, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 591.19 | 571.41 | 570.79 | 556.24 | 552.97 |
Cost Of Goods | 326.93 | 321.54 | 321.42 | 311.63 | 297.46 |
Gross Profit | 264.25 | 249.88 | 249.37 | 244.61 | 255.51 |
SG&A, R&D, and Dept/Amort Expenses | 212.04 | 218.26 | 215.36 | 202.40 | 217.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | 52.21 | 31.62 | 34.01 | 42.21 | 37.79 |
Non-Operating Income | 4.91 | 3.73 | 3.55 | 3.76 | -92.52 |
Interest Expense | 7.90 | 8.12 | 8.23 | 8.02 | 7.50 |
Pretax Income | 49.23 | 27.23 | 29.20 | 37.95 | -62.23 |
Income Taxes | 16.66 | 12.63 | 10.18 | 12.33 | 18.25 |
Minority Interest | 0.27 | 0.19 | -0.30 | -0.34 | -0.21 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 32.57 | 14.59 | 19.02 | 25.62 | -80.48 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 32.30 | 14.40 | 19.32 | 25.96 | -80.28 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 33.05 | 32.98 | 32.91 | 32.83 | 32.58 |
Diluted EPS Before Non-Recurring Items | 1.32 | 1.03 | 0.94 | 0.98 | 1.37 |
Diluted Net EPS (GAAP) | 0.98 | 0.44 | 0.60 | 0.79 | -2.46 |